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Abstract
Sensitive detection of protein aggregates is important for evaluating the quality of
biopharmaceuticals and detecting misfolded proteins in several neurodegenerative
diseases. However, it is challenging to detect extremely low concentrations
(<10 ppm) of aggregated protein in the presence of high concentrations of soluble
protein. Glucagon, a peptide hormone used in the treatment of extreme
hypoglycemia, is aggregation‐prone and forms amyloid fibrils. Detection of glucagon
fibrils using conformation‐specific antibodies is an attractive approach for
identifying such aggregates during process and formulation development. There-
fore, we have used yeast surface display and magnetic‐activated cell sorting to sort
single‐chain antibody libraries to identify antibody variants with high conforma-
tional specificity for glucagon fibrils. Notably, we find several high‐affinity
antibodies that display excellent selectivity for glucagon fibrils, and we have
integrated these antibodies into a sensitive immunoassay. Surprisingly, the
sensitivity of our assay—which involves direct (nonantibody mediated) glucagon
immobilization in microtiter plates—can be significantly enhanced by pretreating
the microtiter plates with various types of globular proteins before glucagon
immobilization. Moreover, increased total concentrations of glucagon peptide also
significantly improve the sensitivity of our assay, which appears to be due to the
strong seeding activity of immobilized fibrils at high glucagon concentrations. Our
final assay is highly sensitive (fibril detection limit of ~0.5–1 ppm) and is >20 times
more sensitive than detection using a conventional, amyloid‐specific fluorescent dye
(Thioflavin T). We expect that this type of sensitive immunoassay can be readily
integrated into the drug development process to improve the generation of safe and
potent peptide therapeutics.
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1 | INTRODUCTION
There is wide‐spread interest in using biologics—ranging from
relatively small peptide hormones to large monoclonal antibodies—
as drugs given their unique properties, including their high affinity
and specificity for their targets and low toxicity and immunogenicity.
In the area of polypeptide therapeutics, the glucose‐regulated
peptide glucagon has proven to be a valuable therapeutic agent that
modulates blood glucose levels. Glucagon is produced through the
tissue‐specific posttranslational processing of preproglucagon
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(White & Saunders, 1986). Glucagon is a first‐line treatment in
addressing extreme hypoglycemia, among other indications (Hall‐
Boyer, Zaloga, & Chernow, 1984). It stimulates glycogenolysis and
gluconeogenesis via binding to the glucagon receptor, resulting in a
signal cascade that rapidly increases blood sugar levels (Unson,
2002). The important biological role of this peptide has motivated
interest in using it for the treatment of extreme hypoglycemia in the
clinic, and has made glucagon a molecule of interest (alongside
insulin) for development of bihormonal pumps that manage blood
sugar levels in individuals with type 1 diabetes (Castle et al., 2010; El‐
Khatib, Russell, Nathan, Sutherlin, & Damiano, 2010; Russell et al.,
2012, 2014; Steiner, Li, Hauser, & Pohl, 2010).
A key challenge in developing biologics as therapeutics is that
they display variable and difficult‐to‐predict levels of aggregation
(Dobson, 1999), which can lead to the presence of aggregated species
in the purified and formulated drug product (Onoue et al., 2004;
Wang, 2005). For highly aggregation‐prone biologics, concerns
regarding batch‐to‐batch variability in drug quality and immunogeni-
city can greatly complicate the downstream stages of bioprocess
development and quality assurance, while also presenting threats to
patient safety. Indeed, native glucagon is well‐known for displaying
poor solubility and high propensity for aggregation into amyloid
fibrils of diverse morphologies (De Jong, Incledon, Yip, & DeFelippis,
2006; Dong, Hovgaard, Xu, Otzen, & Besenbacher, 2006; Ghodke
et al., 2012; Gratzer, Bailey, & Beaven, 1967; Pedersen, 2010;
Pedersen & Otzen, 2008; Pedersen et al., 2006). For instance,
glucagon fibril formation can occur rapidly, and its rate is highly
dependent on the initial concentration of amyloid present in the
sample. Consequently, reconstituted glucagon is generally only stable
over short timeframes and must be solubilized immediately before
use. Such challenges have led to significant efforts in optimizing
formulations to minimize aggregation (Bakhtiani et al., 2015; Pohl, Li,
Krasner, & De Souza, 2015; Steiner et al., 2010; Ward et al., 2010),
enhancing peptide stability and solubility through alterations in
amino acid or chemical composition (Chabenne, DiMarchi, Gelfanov,
& DiMarchi, 2010), and developing assays that detect aggregates
(or the propensity to form aggregates) using fluorescent dyes,
intrinsic tryptophan fluorescence, and other techniques (Hovgaard,
Dong, Otzen, & Besenbacher, 2007; Oliveira et al., 2009; Pedersen
et al., 2006).
Despite this important progress, it remains extremely challenging
to sensitively detect endogenous glucagon aggregates that are
present at extremely low levels (e.g., <10 ppm). Such concentrations
are typically too dilute for detection using conventional methods
such as amyloid‐specific dyes (e.g., Thioflavin T, ThT) and size‐
exclusion chromatography without first stressing the samples to
amplify the amount of aggregate. We reasoned that an enzyme‐
linked immunosorbent assay (ELISA)‐based method could be devel-
oped to achieve much more rapid and sensitive detection of glucagon
amyloid fibrils than conventional methods without the need for
stressing the samples to amplify the aggregates. Due to the lack of
existing conformational antibodies specific for glucagon, we sought
to generate such antibodies using in vitro antibody discovery
methods that involve sorting single‐chain antibody fragment (scFv)
libraries using yeast surface display to identify variants with high
affinity for aggregated glucagon and low affinity for soluble glucagon.
Herein, we report the identification of amyloid‐specific antibodies
that recognize glucagon fibrils and demonstrate an ELISA method
that is much more sensitive than conventional methods.
2 | MATERIALS AND METHODS
2.1 | Preparation of soluble and fibrillated
glucagon
Glucagon powder (Novo Nordisk A/S, Copenhagen, Denmark) was
solubilized at a concentration of 10 g/L in 10mM HCl and sterilized
by using 0.2 µm filters (28145‐501; VWR International, Radnor, PA).
Glucagon was then diluted to a final concentration of 1 g/L (50mM
glycine, pH 2.5). Fibrils were assembled at 37°C with shaking
(900 rpm, 18 hr), and then recovered by ultracentrifugation at
221,000xg for 1 hr at 4°C (Tube PC Thickwall, 1 ml, 45237; Thermo
Fisher Scientific, Waltham, MA). Fibril pellets were washed once and
then resuspended in either the original volume of buffer (50mM
glycine, pH 2.5) for ELISA analysis or phosphate buffered saline (PBS)
for coupling to magnetic beads, sorting, and initial ELISA screening.
Fibril concentrations were determined by bicinchoninic acid (BCA) or
micro BCA assays (23225 or 23235; Thermo Fisher Scientific).
Before use, fibrils were sonicated (FB‐120 Sonic Dismembrator; Ther-
mo Fisher Scientific) on ice for 30 s at 100% amplitude (3 cycles of
10 s on and 30 s off) to reduce fibril size and increase homogeneity,
which is expected to improve their immobilization on magnetic beads
and microtiter plates, as well as to disrupt fibril clumps that form
during ultracentrifugation.
2.2 | Fluorescence analysis of glucagon fibrils
Soluble and fibrillar glucagon were separately diluted to a final
concentration of 245 µM (50mM glycine, pH 2.5). For tryptophan
fluorescence emission scans, sample (50 µl) was added to black 384‐
well plates (12566624; Thermo Fisher Scientific), and intrinsic
fluorescence emission scans were performed from 300 to 500 nm
(λex = 280 nm). For ThT fluorescence emission scans, ThT was added
to the samples at a final concentration of 4 µM (final glucagon
concentration of 200 µM). A 50 µl sample of the peptide/ThT
mixtures was added to the wells of black 384‐well plates, and
fluorescence emission scans were performed from 450 to 550 nm
(λex = 444 nm). All fluorescence readings were performed at room
temperature using a BioTek Synergy Neo microplate reader.
2.3 | Atomic force microscopy
Glucagon fibrils were diluted to a concentration of 50 µM in 50mM
glycine (pH 2.5). A 10 µl sample of glucagon fibrils was deposited on
a 1 × 1 cm sheet of Muscovite Mica (V‐1 Quality, 71855‐05; Electron
Microscopy Sciences, Hatfield, PA) that was attached to a glass slide
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with double‐sided tape. The sample was incubated on the mica
(45min), washed with 1ml of sterile deionized water, and imaged at
room temperature using an Asylum Research Molecular Force Probe
3D. Tapping‐mode (noncontact) imaging in air was used to determine
the morphology of the fibrils. Image processing and analysis of the
force data were conducted using the built‐in features of MFP 3D
software.
2.4 | Cloning of antibody variants
Antibodies (scFvs) specific for glucagon fibrils were isolated using
mutagenesis (Tiller, Chowdhury et al., 2017), yeast surface display
and magnetic sorting using Dynabeads (Dynabeads M‐280 Tosylacti-
vated, 14203; Invitrogen, Carlsbad, CA) coated with immobilized
fibrillar or soluble glucagon using methods related to those reported
previously (Julian et al., 2019). Briefly, 8 × 107 beads were washed
twice with 1ml of PBS. Soluble glucagon (100 µg) was then coupled
to the beads in 800 µl of buffer (50mM borate, pH 9.5) overnight
(4°C, no mixing). Fibrillar glucagon (100 µg) was coupled in 800 µl of
PBS overnight at room temperature with end‐over‐end mixing. The
beads were quenched by washing twice with PBS supplemented with
10mM glycine and then washed with PBS supplemented with 1 g/L
bovine serum albumin (BSA; PBS‐B) before incubation with yeast. All
positive selections were performed against fibrillar glucagon in
PBS‐B supplemented with 1% milk, and the negative selections were
performed against soluble glucagon in PBS‐B.
Following eight rounds of yeast sorting, the plasmid DNA for the
enriched yeast libraries was recovered with the Zymoprep Yeast
Plasmid Miniprep II Kit (D2004; Zymo Research, Irvine, CA). The
isolated scFv genes were amplified with Phusion High‐Fidelity DNA
Polymerase (M0530L; New England Biolabs, Ipswich, MA), and
cloned by standard DNA restriction and ligation methods. The scFv
genes were cloned between the NcoI and NotI restriction sites of anti‐
Notch1_E6‐pBIOCAM5, which was a gift from John McCafferty
(Plasmid # 39344, Addgene, Watertown, MA; Falk et al., 2012). The
resulting constructs encoded a bivalent scFv‐human Fc fusion protein
containing C‐terminal 6xHis and 3xFLAG tags, and their DNA
sequences were determined by Sanger sequencing.
2.5 | Antibody expression and purification
The antibodies were expressed transiently in adherent HEK 293T
cells (CRL‐3216; ATCC, Manassas, VA) using Invitrogen Lipofecta-
mine 2000 Transfection Reagent (11668019; Thermo Fisher Scien-
tific), as described previously (Julian et al., 2019; Rabia, Zhang,
Ludwig, Julian, & Tessier, 2019; Tiller, Li et al., 2017). Briefly, cells
were cultured in ~15ml of Dulbecco’s Modified Eagle's Medium
(DMEM) culture media (10569‐044; Thermo Fisher Scientific)
supplemented with 10% fetal bovine serum (35010CV; Corning,
Corning, NY) and 1% penicillin/streptomycin (15140122; Thermo
Fisher Scientific) in 75 cm2 cell culture flasks (0030711122; Eppen-
dorf, Hamburg, Germany) until reaching ~80% confluence. Lipofec-
tamine 2000 (20 µg/flask) and plasmid DNA (8 µg/flask) were
separately added to 0.5 ml OPTI‐MEM media (31985‐062; Thermo
Fisher Scientific) and incubated for 10min. Lipofectamine and DNA
were then mixed and allowed to incubate for 30min. Spent media in
the flasks was replaced with the media (15ml of DMEM) containing
DNA and lipofectamine, and the cells were cultured for 3–4 days at
37°C under 5% CO2. The media containing secreted antibody was
harvested and centrifuged at 2,500xg for 5 min to remove the cells.
The secreted antibodies were purified via Protein A (20334; Ther-
mo Fisher Scientific). Culture media was incubated with 1ml (50%
slurry) of Protein A agarose resin overnight at 4°C on a rocking plate.
The resin was collected by vacuum filtration in a 10ml purification
column (89898; Thermo Fisher Scientific), and the resin was washed
with 100ml of PBS. The antibodies were then incubated with
1.5ml of 0.1M glycine buffer (pH 2.5) for 15min and eluted via
centrifugation. The pH of the eluted protein solutions was adjusted
to near‐neutral pH by addition of one‐tenth of the elution volume
of potassium phosphate (1M), and the antibodies were buffer
exchanged into PBS using Zeba Spin Desalting Columns
(89891; Thermo Fisher Scientific). Protein concentrations were
determined using the micro BCA assay or by measuring absorbance
at 280 nm (extinction coefficients of 168,460–205,360M−1 cm−1)
before use, and protein purity was confirmed by sodium dodecyl
sulfate‐polyacrylamide gel electrophoresis.
2.6 | Antibody binding analysis
2.6.1 | Initial screening of antibodies
Glucagon was diluted to 25 µM in buffer (50 mM glycine, pH 2.5) for
preparing the soluble peptide or in PBS for preparing the fibrillar
peptide, and 100 µl of sample was incubated overnight at 4°C in
Nunc MaxiSorp 96‐well ELISA plates (439454; Thermo Fisher
Scientific). All primary and secondary antibody binding steps were
performed in PBS supplemented with 0.1% Tween 20 and 1 g/L BSA
(PBST‐B), and the sample volumes were 100 µl (unless otherwise
specified). Wash steps between incubations were performed three
times with PBS (300 µl). The antibodies were diluted to a
concentration of 0.5 nM in PBST‐B and incubated with immobilized
glucagon for 1 hr at room temperature. After washing, secondary
antibody (Invitrogen Goat anti‐Human IgG Fc HRP‐conjugate,
A18817; Thermo Fisher Scientific) was diluted 1:1000 (stock
concentration of 0.5 mg/mL) into PBST‐B and incubated for 1 hr
at room temperature. Antibody binding was detected by addition of
100 µl of 1‐Step Ultra‐TMB ELISA Substrate Solution (34028; Ther-
mo Fisher Scientific) to each well, and reactions were quenched
with 2M sulfuric acid (100 µl) after formation of the colored
product. For all reported assays, reactions were quenched after
3–5min. The absorbance of each well was measured at 450 nm
using a Biotek Synergy Neo microplate reader. Reported signal
ratios represent the ratio of the ELISA signal for wells coated with
fibrillar glucagon relative to signal for wells coated with soluble
glucagon at an equivalent concentration.
Binding curves for the most promising antibodies were generated
using the following procedure. First, soluble or fibrillar glucagon was
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diluted to 2.5 µM (50mM glycine, pH 2.5), and 100 µl of sample was
incubated overnight at 4°C in Nunc MaxiSorp 96‐well ELISA plates.
After washing, the antibodies were added to the wells at a range of
concentrations in PBST‐B. Antibodies were incubated for 1 hr at
room temperature. The sequence specificity of the antibodies for
glucagon fibrils was examined using human Aβ1‐42,
α‐synuclein, and islet amyoid polypeptide (IAPP) fibrils. The respective
antigens were immobilized to the plates overnight at 4°C at a
concentration of 2.5 µM. After washing, the antibodies were incubated
at concentrations of 0.5 and 5 nM in PBST‐B for 1 hr at room
temperature. Secondary antibody binding and substrate development/
quenching were performed as described above.
2.6.2 | Screening assay conditions for optimal
antibody sensitivity
Three different types of ELISA plates and three primary antibody binding
solutions were used to study the robustness of the ELISA assay. Soluble
and fibrillar glucagon were separately immobilized (50mM glycine, pH
2.5) for 2 hr (room temperature) using a range of peptide concentrations
(0.0005–25 µM) in MaxiSorp (439454; Thermo Fisher Scientific), medium
binding (655080; Greiner Bio‐One, Kremsmünster, Austria), and high
binding (655081; Greiner Bio‐One) 96‐well ELISA plates. After washing,
antibody (0.5 nM) was added for fibril detection.
The effect of solution conditions during the primary antibody
binding step of the immunoassay was also investigated. Soluble and
fibrillar glucagon were immobilized (2.5 µM) in the wells of
MaxiSorp plates overnight at 4°C. After washing, primary anti-
bodies were incubated at a range of concentrations (0.5, 5, and
50 nM) with the immobilized peptides for 1 hr at room temperature
in (a) PBS supplemented with 0.1% Tween 20 and 1 g/L BSA
(PBST‐B), (b) PBS supplemented with 0.1% Tween 20 and 100 g/L
BSA, and (c) PBS supplemented with 0.1% Tween 20, 1 g/L BSA, and
0.1% milk. Secondary antibody binding and substrate addition and
quenching were performed as previously described.
2.6.3 | Detection of glucagon fibrils in mixtures of
soluble and fibrillar glucagon
Mixtures of fibrillar and soluble glucagon containing a wide range of
initial concentrations of fibril were prepared at a total glucagon
concentration of 200 µM (50mM glycine, pH 2.5). The mixtures were
incubated in Nunc MaxiSorp 96‐well plates and allowed to bind for
2 hr (room temperature). After washing, the primary antibodies
(0.5 nM) were incubated for 1 hr at room temperature (PBST‐B).
Secondary binding and substrate development and quenching were
performed as previously described. For ThT detection of glucagon
fibrils, mixtures were prepared at a total concentration of 245 µM
(50mM glycine, pH 2.5) and incubated in microcentrifuge tubes for
2 hr. ThT was added (final concentrations of 4, 40, and 400 µM)
while maintaining the final glucagon concentration at 200 µM. After
5–10min, 50 µl of sample was added to black 384‐well plates
(Fisherbrand 384 Well Polystyrene Plates; 12566624; Thermo Fisher
Scientific), and ThT fluorescence (λex = 444 nm and λem = 482 nm)
values were measured using a Biotek Synergy Neo microplate reader.
2.6.4 | Optimization of ELISA microtiter plates by
pretreatment with globular proteins
Nunc MaxiSorp plates were coated with four different globular
proteins of varying isoelectric point (BSA [pI of ~4.7], ovalbumin
[pI of ~4.5], lysozyme [pI of ~11], and avidin [pI of ~10]). Proteins
were dissolved at 1 g/L in PBS, filtered, and immobilized overnight at
4°C. After washing, mixtures of soluble and fibrillar glucagon (total
peptide concentration of 200 µM) were incubated in the plates for
2 hr at room temperature. Surface‐immobilized fibrils were detected
by incubation with primary antibody (0.5 nM) in PBST‐B for 1 hr at
room temperature, and antibody detection was performed as
described above.
2.6.5 | Effect of glucagon concentration on ELISA
sensitivity
MaxiSorp plates were coated with 1 g/L BSA (PBS, filtered) overnight
at 4°C. Mixtures of soluble and fibrillar glucagon were prepared in
50mM glycine (pH 2.5) at a total glucagon concentration of 2, 20, and
200 µM. The mixtures were incubated in well plates for 2 hr at room
temperature, the plates were washed, and fibrils were detected using
primary antibody (0.5 nM) in PBST‐B, with secondary incubation and
substrate addition and quenching performed as described above.
3 | RESULTS
3.1 | Identification of conformational antibodies
specific for glucagon amyloid fibrils
Our first step toward selection of conformational antibodies against
glucagon amyloid fibrils involved antigen assembly and characteriza-
tion for subsequent use during antibody selection. Glucagon peptide
(3483Da) is only sparingly soluble at neutral pH, which led us to
evaluate other conditions for forming fibrils in a well defined manner.
We chose to assemble fibrils at pH 2.5 (50mM glycine) based on
previous work that demonstrated reproducible fibril formation at
these conditions, and also because lyophilized glucagon powder
is reconstituted at acidic pH for pharmaceutical administration
(Pedersen et al., 2006). The fibrils formed over a period of 18 hr
and were recovered via ultracentrifugation. The properties of the
resulting aggregates were studied using an amyloid‐specific dye
(ThT), intrinsic tryptophan fluorescence, and atomic force microscopy
(AFM; Figure 1). The amyloid nature of the fibrils was confirmed by
relatively high ThT fluorescence (Figure 1a), a significant blue‐shift in
the intrinsic tryptophan fluorescence emission maxima relative to
soluble glucagon (Figure 1b), and fibril‐like morphology as revealed
by AFM (Figure 1c).
Next, we sought to screen for antibodies with selective affinity
for glucagon fibrils. The antibody library that was used for yeast
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surface display was prepared using the variable regions from 4D5
(Albanell & Baselga, 1999) with diversification at 15 sites in heavy
chain CDR3 (HCDR3; Tiller, Chowdhury et al., 2017). The DNA
encoding the antibody library was fused to a yeast cell‐surface
protein (Aga2). Antibodies expressed on the surface of yeast were
sorted via negative selections against magnetic beads coated with
soluble glucagon, while positive sorts were performed against beads
coated with fibrillar glucagon.
Following eight rounds of iterative negative and positive sorting
(pH 7.4), the enriched antibody library was recovered, cloned as scFv‐
Fc antibodies, and sequenced. We identified 23 unique antibodies,
which were subsequently expressed in HEK 293T and purified using
Protein A chromatography. Next, we examined the conformational
specificity of the antibodies by immobilizing soluble and fibrillar
glucagon (25 µM) in 96‐well ELISA microtiter plates (Figure 2).
Binding of the antibodies was assessed at a relatively low
concentration (0.5 nM). A majority of the 23 antibodies displayed
high degrees of conformational specificity for glucagon fibrils relative
to the soluble peptide, while also displaying low levels of background
binding to uncoated ELISA plates.
The conformational specificity of four of the most promising
antibodies was evaluated at neutral pH in more detail by testing a
range of primary antibody concentrations (Figure 3). Even at high
antibody concentrations (> 100 nM), we observed high conformational
specificity, with concentrations between 0.5 and 5 nM providing the
greatest discrimination between the soluble and fibrillar forms of
glucagon. Notably, the four antibody variants performed similarly in this
experiment (EC50 values of 0.28–0.4 nM for glucagon fibrils), which led
us to further assess their binding to other amyloid species (human Aβ1‐
42, α‐synuclein, and IAPP fibrils; Figure S1). Unexpectedly, we observed
that the antibody variants recognized some of the nonglucagon fibrils.
Relative to glucagon fibrils, the antibodies displayed increased binding
to IAPP fibrils, reduced binding to Aβ1‐42 fibrils, and little binding to
α‐synuclein fibrils. It was unclear why the glucagon antibodies reacted
with some nonglucagon amyloids and not others, and it is not possible
F IGURE 1 Characterization of glucagon fibril assembly. Glucagon
fibrils were assembled at a concentration of 1 g/L in 50mM glycine
(pH 2.5) using agitation (900 rpm) at 37°C. The amyloid nature of the
resulting peptide aggregates was evaluated using (a) Thioflavin T
fluorescence (emission scans, λex = 444 nm), (b) tryptophan (intrinsic)
fluorescence (emission scans, λex = 280 nm), and (c) atomic force
microscopy [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 2 Evaluation of the conformational specificity of a panel of glucagon antibodies. Soluble and fibrillar glucagon were separately
immobilized overnight in Nunc MaxiSorp ELISA plates at a concentration of 25µM (4°C), and the specificity of each antibody (0.5nM) for fibrillar
glucagon relative to soluble peptide was determined. The reported specificity ratios are the raw ELISA signals for antibodies binding to
immobilized glucagon fibrils relative to either immobilized soluble glucagon (blue) or nontreated microtiter plates (background, red). Error bars
represent standard errors. ELISA: enzyme‐linked immunosorbent assay [Color figure can be viewed at wileyonlinelibrary.com]
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to predict the antibody reactivity with other amyloidogenic polypep-
tides without further experimental analysis. Collectively, these results
demonstrate that the glucagon antibodies recognize glucagon fibrils
with high conformational specificity and cross‐react with a subset of
non‐glucagon amyloids.
We next sought to evaluate the impact of various factors on the
the performance of our immunoassay. Considering that glucagon is a
relatively small peptide and different types of ELISA plates are
optimized for immobilization of distinct sizes, classes, and types of
biomolecules, we sought to examine if specific types of ELISA plates
offered improved assay sensitivity. However, we observed similar
performance for three types of ELISA plates (Figure S2), suggesting
that assay performance was weakly influenced by the plate surface.
We also evaluated the impact of the solution conditions used during
antibody binding on assay performance (Figure S3). Addition of high
concentrations of BSA (100mg/ml) during antibody binding led to
relatively small effects on assay performance. However, addition of
0.1% milk during primary antibody binding inhibited recognition of
glucagon fibrils. These results indicate that the antibodies recognize
glucagon amyloid fibrils via molecular interactions that can be
blocked by the components in milk.
3.2 | Optimization of ELISA detection of glucagon
fibrils
To mimic detection of low levels of endogenous glucagon amyloids in
the final drug product, we next sought to test if our antibodies could
detect low concentrations of glucagon fibrils in the presence of a
large excess of soluble glucagon (Figure 4). Therefore, we prepared
mixtures of fibrillar and soluble glucagon containing low initial
concentrations of fibril (0–10 nM) at total glucagon concentrations of
200 µM (~0.7 g/L). These mixtures were incubated in ELISA plates for
2 hr at room temperature. Encouragingly, wells incubated with
glucagon samples initially containing ≥1 nM of fibril gave rise to
detectable antibody binding signals. For comparison, fibril/soluble
glucagon mixtures were prepared and incubated with the amyloid‐
specific fluorescent dye ThT (2 hr, final glucagon concentration of
200 µM after addition of ThT). Importantly, ThT fluorescence above
background was only detected at initial glucagon fibril concentra-
tions ≥~10 nM (Figure 4). These results demonstrate that our initial
immunoassay is an order of magnitude more sensitive than a
conventional amyloid detection assay. The concentration of ThT also
impacted the sensitivity of glucagon amyloid detection, as we find
concentrations of ThT > 40 µM reduced sensitivity (Figure S4).
We reasoned that the sensitivity of our ELISA assay could be
enhanced by using our antibodies as capture reagents in a sandwich
ELISA format. However, our initial efforts at developing a sandwich
ELISA revealed that glucagon fibrils were efficiently immobilized even if
the ELISA plates were first blocked (data not shown). This interesting
result led us to explore whether the surface of the ELISA plates could be
F IGURE 3 Characterization of the concentration‐dependent
binding of glucagon antibodies. The specificity of antibodies for
glucagon fibrils relative to soluble glucagon was evaluated using
glucagon immobilized in MaxiSorp plates (2.5 µM). The reported
values are normalized ELISA signals. Average values for three
independent experiments are reported, while the error bars are
standard errors. The data are fit using three‐parameter Hill
equations. ELISA: enzyme‐linked immunosorbent assay [Color figure
can be viewed at wileyonlinelibrary.com]
F IGURE 4 Comparison of glucagon amyloid detection using
conformational antibodies and an amyloid‐specific fluorescent dye
(ThT). Antibody detection was performed using mixtures of soluble
and fibrillar glucagon prepared at a total glucagon concentration of
200µM and immobilized in ELISA plates for 2hr. ThT detection (4µM
ThT) was performed for mixtures of soluble and fibrillar glucagon
prepared at a total glucagon concentration of 245µM, incubated in
microcentrifuge tubes for 2hr, and diluted to a final glucagon
concentration of 200µM. For antibody detection, the values
represent the mean for four independent experiments. For ThT
detection, the values represent the mean for three independent
experiments. The reported values for antibody and ThT detection of
glucagon fibrils are normalized to the values obtained for soluble
glucagon, and the error bars represent standard
errors. ELISA: enzyme‐linked immunosorbent assay [Color figure can
be viewed at wileyonlinelibrary.com]
STIMPLE ET AL. | 1873
optimized for fibril capture by pretreatment with different globular
proteins before incubation with glucagon (Figure 5). Four different
globular proteins with varying isoelectric points (BSA, pI of ~4.7;
ovalbumin, pI of ~4.5; lysozyme, pI of ~11; and avidin, pI of ~10) were
used to treat the MaxiSorp plates before incubation with the mixtures
of soluble and fibrillar glucagon. Relative to untreated plates, pretreat-
ment with BSA and ovalbumin significantly improved assay sensitivity
(~5‐fold and ~2‐fold increases in sensitivity, respectively). In contrast,
pretreatment with lysozyme led to modest improvements and
pretreatment with avidin decreased assay performance.
Finally, we evaluated the performance of our optimized assay as a
function of the total glucagon concentration (Figure 6). BSA‐treated
plates were used to immobilize glucagon mixtures at three different total
glucagon concentrations (2, 20, and 200 µM), and the assay signal was
compared for data points collected at the same initial fibril concentra-
tions. We find that 10‐fold increases in total peptide concentration
correspond to ~10‐fold increases in assay sensitivity (Figure 6a). This
result is likely due to enhanced fibril seeding at high glucagon
concentrations. We also analyzed the results in terms of the percentage
of fibril initially present in the sample mixture (Figure 6b). These results
demonstrate that our optimized assay is capable of detecting extremely
low (0.5–1ppm) levels of glucagon fibrils that are far more dilute than can
be detected using conventional (Thioflavin T) methods (~50 ppm).
4 | DISCUSSION
We have reported the discovery of a panel of conformational
antibodies that recognize glucagon amyloids with high conformational
specificity, as well as the optimization of an ELISA for sensitive
detection of aggregates. Interestingly, our antibodies also cross‐react
with a subset of fibrils of other amyloidogenic polypeptides. While
antibody sequence promiscuity would normally represent a concern
during the development of a sensitive immunoassay, antibody
recognition of different types of amyloids does not present an issue
for detection of glucagon fibrillation in purified and formulated drug
product. These results also raise the intriguing possibility that our
antibodies may recognize conserved amyloid structural motifs, such as
β‐sheets or an amyloid‐specific arrangement of the peptide backbone.
This would be consistent with previous identification of conforma-
tional antibodies that recognize a broad range of prefibrillar or fibrillar
conformers formed by different amyloidogenic polypeptides (Hrncic
et al., 2000; Isas et al., 2010; Kayed & Glabe, 2006; Kayed et al., 2003,
2007; O'Nuallain & Wetzel, 2002; Wu et al., 2010). Interestingly,
glucagon itself is known to form at least five distinct morphologies of
amyloids that differ in their biophysical properties and ThT staining
(De Jong et al., 2006; Gratzer et al., 1967; Pedersen, 2010; Pedersen &
Otzen, 2008; Pedersen et al., 2006). Consequently, antibodies capable
of recognizing different types of glucagon fibrils likely to form
during processing and storage would provide a more comprehensive
analysis of glucagon product quality. We are currently working to
understand which types of glucagon fibrils are recognized in our ELISA
method.
We also observed a striking enhancement of ELISA sensitivity
(~100‐fold) when fibrils are present in glucagon samples containing
high concentrations of soluble glucagon. Using untreated MaxiSorp
microtiter plates, the antibodies recognized purified, immobilized
glucagon fibrils at concentrations ≥100 nM, but detected fibrils in
F IGURE 5 Preblocking microtiter
plates with globular proteins before
glucagon immobilization enhances ELISA
sensitivity. The performance of antibody
detection of glucagon fibrils was compared
using control (untreated) ELISA plates
(dashed lines) and plates preblocked with
four different globular proteins (solid lines)
before glucagon sample incubation. The
reported values represent the mean for at
least three independent experiments, and
error bars are standard errors. BSA: bovine
serum albumin; ELISA: enzyme‐linked
immunosorbent assay [Color figure can be
viewed at wileyonlinelibrary.com]
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mixtures with soluble peptide at much lower initial concentrations
(as low as ~1 nM). This finding suggests that extremely low fibril
concentrations are efficient at seeding during short incubation times
(2 hr), even without agitation. It is possible that (a) fibrils are
immobilized and then are amplified via seeding, (b) fibrils are
amplified via seeding in solution and then immobilized or (c) fibril
seeding occurs both in solution and after immobilization. Regardless
of the exact mechanism, it is likely that glucagon fibril seeding
amplifies the detection sensitivity of our ELISA method.
Another contributing factor to the sensitivity of our assay is that
glucagon fibrils were immobilized even when we first preblocked the
ELISA plate with globular proteins. Notably, preblocking the plates
with acidic proteins (BSA and ovalbumin, pIs of ~4.5–4.7) improved
assay performance, while basic proteins (lysozyme and avidin,
pIs > 10) had little or negative impacts. The mechanism through
which acidic proteins such as BSA enhance the ELISA signal remains
unclear. BSA may improve immobilization of glucagon fibrils and/or
reduce immobilization of soluble glucagon. It is notable that the
glucagon samples were immobilized at pH 2.5, which is well below
the isoelectric points of BSA (pI of ~4.7) and glucagon (pI of ~7.1).
Therefore, electrostatic interactions do not appear to explain the
mechanism by which BSA and ovalbumin improve assay performance.
Alternatively, nonelectrostatic interactions—such as hydrophobic
interactions—between the albumins and glucagon fibrils may
promote glucagon fibril immobilization relative to soluble glucagon
immobilization. Regardless of the exact mechanism, it is clear that
albumins modify the microtiter plate surface in a manner that
enhances detection sensitivity, and this finding may be valuable for
improving the detection of other amyloid‐forming proteins in related
types of ELISAs.
Finally, it is important to consider the practical implications of
using our ELISA method for detecting glucagon aggregation relative
to the conventional method (ThT fluorescence). Most previous
studies using ThT to detect low levels of amyloid require agitation
and long incubations (hours to days) to enhance fibril seeding and
amplification of pre‐existing aggregates (Pedersen & Otzen, 2008;
Pedersen et al., 2006). The need for agitation over long times is likely
linked to the well‐known problems with poor reproducibility of ThT
assays. Our approach requires relatively short incubation times (2 hr)
without agitation, which results in increased reproducibility. Our
future work aims to improve antibody affinity to further enhance the
sensitivity of the assay for detecting endogenous glucagon aggre-
gates without the need for first amplifying the aggregates.
5 | CONCLUSIONS
Protein aggregation is a critical concern during the manufacture,
formulation, and storage of a wide range of biopharmaceuticals (Lowe
et al., 2011; Perchiacca & Tessier, 2012; Shire, 2009). Therefore, it is
particularly important to develop analytical methods and reagents for
analysis of biopharmaceutical product quality for aggregation‐prone
polypeptides. We expect that our discovery of antibodies that
recognize glucagon amyloid fibrils with high conformational specificity
will improve the detection of aggregates using fast, simple, and
reproducible ELISA methods. Our assay is much more sensitive than
conventional (ThT) methods and does not require agitation to amplify
pre‐existing aggregates. Importantly, we find that glucagon fibril
detection can be enhanced by pretreating ELISA plates with globular
proteins and that fibril seeding during antigen immobilization greatly
improves assay sensitivity. We expect that additional future research
will enable even greater improvements in detection sensitivity and
lead to extremely sensitive detection of peptide aggregates during the
drug development process.
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